Cover Image
市場調查報告書

PharmaPoint:大腸躁鬱症 (IBS) - 全球醫藥品市場2023年為止的預測與市場分析

PharmaPoint: Irritable Bowel Syndrome - Global Drug Forecast and Market Analysis to 2023

出版商 GlobalData 商品編碼 325932
出版日期 內容資訊 英文 255 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:大腸躁鬱症 (IBS) - 全球醫藥品市場2023年為止的預測與市場分析 PharmaPoint: Irritable Bowel Syndrome - Global Drug Forecast and Market Analysis to 2023
出版日期: 2014年12月31日 內容資訊: 英文 255 Pages
簡介

大腸躁鬱症 (IBS)是常見的障礙,關係到腸道機能的變化,特徵是腹部的不適感。IBS雖然不是生死攸關的疾,但會強烈影響患者的生活品質 (QOL) 。

本報告提供全球大腸躁鬱症 (IBS) 的治療藥市場相關調查分析,提供您疾病概要與指南,競爭情形,主要藥物的詳細資訊 (產品說明,安全性,有效性) 、SWOT分析,銷售額預測,影響分析 (趨勢,推動因素·阻礙因素) 等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
  • 分類
  • 症狀
  • 預後
  • 生活品質 (QOL)

第4章 流行病學

  • 疾病的背景
  • 危險因素和併發症
  • 全球趨勢
  • 預測手法
  • IBS的流行病學預測
  • 議論

第5章 疾病的管理

  • 診斷和治療概要
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第6章 競爭評估

  • 概要
  • 產品簡介:領導品牌
  • 其他藥效分類

第7章 未滿足需求和機會

  • 概要
  • 更有效的藥物療法
  • IBS D類型的治療方法
  • IBS M類型的治療方法
  • 解決腹痛和飽脹感症狀的治療方法
  • 提高IBS的診斷率

第8章 開發平台評估

  • 概要
  • 臨床試驗製圖
  • 臨床開發中的潛力藥物
  • 產品簡介:後期開發平台 (IBS D)
  • 產品簡介:後期開發平台 (IBS C)
  • 其他

第9章 現在·未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介

第10章 市場預測

  • 全球市場
  • 美國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第11章 附錄

圖表

目錄
Product Code: GDHC97PIDR

Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients' quality of life (QOL). In terms of volume, the IBS market is a large, albeit naive, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.

As of October 2014, there were four products indicated for IBS in the 7MM. These include the constipation-predominant IBS (IBS-C) therapies, Sucampo/Takeda/Abbott's Amitiza (lubiprostone) and Ironwood/Actavis/Almirall/Astellas' Linzess (linaclotide), and the diarrhea-predominant IBS (IBS-D) therapies, Prometheus' Lotronex (alosetron) and Astellas' Irribow (ramosetron). Antidepressants and antibiotics (mainly Salix/Alfa Wassermann/Norgine/Bama-Geve's Xifaxan [rifaximin]), are also commonly used off-label to treat IBS. GlobalData anticipates that four new therapies have the potential to enter the IBS market during the 2013-2023 forecast period. This includes Furiex's (Actavis') eluxadoline and Menarini's ibodutant for IBS-D, and Synergy's plecanatide and AstraZeneca/Ardelyx's tenapanor for IBS-C. In addition, Xifaxan is in development for IBS-D, and has the potential to gain a label expansion for this indication during the forecast period.

Highlights

Key Questions Answered

  • What do physicians think about Ironwood/Actavis/Almirall/Astellas' Linzess and what will be the impact in the IBS market following its launch in 2012 in the US and 2013 in the 5EU region?
  • What will be the uptake of Salix/Alfa Wassermann/Norgine/Bama-Geve's Xifaxan following its anticipated label-expansion for IBS-D and how will it impact the treatment paradigm for IBS?
  • What is the significance of late-phase pipeline products for IBS and how will their launch shape the future treatment landscape in IBS?
  • What are the significant unmet needs in the IBS market?
  • What are the remaining opportunities in the IBS market?

Key Findings

  • The IBS market value will be driven by the increasing uptake of Ironwood/Actavis/Almirall/Astellas' Linzess and its expected launch in all the major European markets and Japan, the anticipated label expansion of Salix/Alfa Wassermann/Norgine/Bama-Geve's Xifaxan for IBS-D, the potential introduction of four pipeline drugs for the treatment of IBS, and the increasing prevalent cases of IBS.
  • The main corporate strategy trend in the IBS market is for companies to enter into partnerships for the successful co-development and co-marketing of products in the different global regions.
  • The most pressing unmet need in the IBS market is for the development of drugs with improved efficacy.

Scope

  • Overview of IBS, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options.
  • Annualized IBS therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the IBS market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of mid-stage pipeline drugs.
  • Analysis of the current and future market competition in the global IBS market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global IBS market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global IBS market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global IBS market from 2013-2023.
  • Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Classification
  • 3.3. Symptoms
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
    • 4.3.1. US
    • 4.3.2. 5EU
    • 4.3.3. Japan
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Sources Not Used
    • 4.4.3. Forecast Assumptions and Methods - Total Prevalent Cases of IBS
    • 4.4.4. Forecast Assumptions and Methods - IBS Subtype Segmentations
  • 4.5. Epidemiological Forecast for IBS (2013-2023)
    • 4.5.1. Total Prevalent Cases of IBS
    • 4.5.2. Age-Specific Total Prevalent Cases of IBS
    • 4.5.3. Sex-Specific Total Prevalent Cases of IBS
    • 4.5.4. Age-Standardized Total Prevalence of IBS
    • 4.5.5. Total Prevalent Cases of IBS by Clinical Subtype
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Disease Management

  • 5.1. Diagnosis and Treatment Overview
    • 5.1.1. Diagnosis
    • 5.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 5.1.3. Clinical Practice
  • 5.2. US
  • 5.3. France
  • 5.4. Germany
  • 5.5. Italy
  • 5.6. Spain
  • 5.7. UK
  • 5.8. Japan

6. Competitive Assessment

  • 6.1. Overview
  • 6.2. Product Profiles - Major Brands, IBS-C
    • 6.2.1. Amitiza (lubiprostone)
    • 6.2.2. Linzess (linaclotide)
  • 6.3. Product Profiles - Major Brands, IBS-D
    • 6.3.1. Lotronex (alosetron)
    • 6.3.2. Irribow (ramosetron)
  • 6.4. Product Profiles - Major Brands, Other
    • 6.4.1. Antidepressants
  • 6.5. Other Therapeutic Classes

7. Unmet Need and Opportunity

  • 7.1. Overview
  • 7.2. More Effective Pharmacotherapies
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. Therapies for the IBS-D Subtype
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunity
  • 7.4. Therapies for the IBS-M Subtype
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity
  • 7.5. Therapies to Address Abdominal Pain and Bloating Symptoms
    • 7.5.1. Unmet Need
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunity
  • 7.6. Improved Diagnosis Rate for IBS
    • 7.6.1. Unmet Need
    • 7.6.2. Gap Analysis
    • 7.6.3. Opportunity

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Clinical Trial Mapping
    • 8.2.1. Clinical Trials by Therapy Type
  • 8.3. Promising Drugs in Clinical Development
  • 8.4. Product Profiles - Late-Stage Pipeline, IBS-D
    • 8.4.1. Eluxadoline
    • 8.4.2. Ibodutant (MEN-15596)
    • 8.4.3. Xifaxan (rifaximin)
  • 8.5. Product Profiles - Late-Stage Pipeline, IBS-C
    • 8.5.1. Plecanatide
    • 8.5.2. Tenapanor (AZD1722, RDX5791)
  • 8.6. Other Drugs in Development for IBS

9. Current and Future Players

  • 9.1. Overview
  • 9.2. Trends in Corporate Strategy
  • 9.3. Company Profiles
    • 9.3.1. Actavis
    • 9.3.2. Astellas
    • 9.3.3. Almirall
    • 9.3.4. Ironwood
    • 9.3.5. Takeda
    • 9.3.6. Sucampo
    • 9.3.7. Prometheus
    • 9.3.8. Salix
    • 9.3.9. Menarini
    • 9.3.10. Synergy
    • 9.3.11. AstraZeneca

10. Market Outlook

  • 10.1. Global Markets
    • 10.1.1. Forecast
    • 10.1.2. Drivers and Barriers - Global Issues
  • 10.2. US
    • 10.2.1. Forecast
    • 10.2.2. Key Events
    • 10.2.3. Drivers and Barriers
  • 10.3. France
    • 10.3.1. Forecast
    • 10.3.2. Key Events
    • 10.3.3. Drivers and Barriers
  • 10.4. Germany
    • 10.4.1. Forecast
    • 10.4.2. Key Events
    • 10.4.3. Drivers and Barriers
  • 10.5. Italy
    • 10.5.1. Forecast
    • 10.5.2. Key Events
    • 10.5.3. Drivers and Barriers
  • 10.6. Spain
    • 10.6.1. Forecast
    • 10.6.2. Key Events
    • 10.6.3. Drivers and Barriers
  • 10.7. UK
    • 10.7.1. Forecast
    • 10.7.2. Key Events
    • 10.7.3. Drivers and Barriers
  • 10.8. Japan
    • 10.8.1. Forecast
    • 10.8.2. Key Events
    • 10.8.3. Drivers and Barriers

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Diagnosed IBS Patients
    • 11.4.2. Drugs Included in Each Therapy Type
    • 11.4.3. Launch and Patent Expiry Dates
    • 11.4.4. General Pricing Assumptions
    • 11.4.5. Individual Drug Assumptions
    • 11.4.6. Generic Erosion
    • 11.4.7. Pricing of Pipeline Agents
  • 11.5. Primary Research - KOLs Interviewed for This Report
  • 11.6. Primary Research - Prescriber Survey
  • 11.7. About the Authors
    • 11.7.1. Analyst
    • 11.7.2. Therapy Area Director
    • 11.7.3. Epidemiologist
    • 11.7.4. Global Head of Healthcare
  • 11.8. About GlobalData
  • 11.9. Disclaimer

List of Tables

  • Table 1: Common Symptoms of IBS
  • Table 2: Risk Factors and Comorbidities for IBS
  • Table 3: Comparison of the IBS Diagnostic Criteria Used in Epidemiological Studies
  • Table 4: Total Prevalence (%) of IBS in the 7MM, as Reported in Epidemiological Studies
  • Table 5: Total Prevalence (%) of IBS in the US, as Reported in Epidemiological Studies
  • Table 6: 7MM, Sources of Total Prevalence Data Used to Forecast the Total Prevalent Cases of IBS
  • Table 7: 7MM, Sources of IBS Subtype Data Used to Forecast the Total Prevalent Cases of IBS by Subtype
  • Table 8: 7MM, Total Prevalent Cases of IBS, Ages ≥10 Years, Both Sexes, N, Selected Years 2013-2023
  • Table 9: 7MM, Age-Specific Total Prevalent Cases of IBS, Both Sexes, N (Row %), 2013
  • Table 10: 7MM, Sex-Specific Prevalent Cases of IBS, Ages ≥10 Years, N (Row %), 2013
  • Table 11: 7MM Total Prevalent Cases of IBS, N (%), by Clinical Subtype, Both Sexes, Ages ≥10 Years, 2013
  • Table 12: Summary of the Various Diagnostic Criteria Used for the Diagnosis of IBS
  • Table 13: Treatment Guidelines for IBS
  • Table 14: Leading Prescribed Drugs for IBS by Predominant Symptoms in the 7MM, 2014†
  • Table 15: IBS Diagnosis and Treatment Country Profile - US
  • Table 16: IBS Diagnosis and Treatment, Country Profile - France
  • Table 17: IBS Diagnosis and Treatment, Country Profile - Germany
  • Table 18: IBS Diagnosis and Treatment, Country Profile - Italy
  • Table 19: IBS Diagnosis and Treatment, Country Profile - Spain
  • Table 20: IBS Diagnosis and Treatment, Country Profile - UK
  • Table 21: IBS Diagnosis and Treatment, Country Profile - Japan
  • Table 22: Leading Branded Treatments for IBS, 2014
  • Table 23: Product Profile - Amitiza
  • Table 24: Safety of Amitiza - Most Frequently Reported Adverse Events
  • Table 25: Amitiza SWOT Analysis, 2014
  • Table 26: Global IBS Sales Forecasts ($m) for Amitiza, 2013-2023
  • Table 27: Product Profile - Linzess
  • Table 28: Efficacy Responder Rates in Linzess' Two Placebo-Controlled IBS-C Trials: At Least Nine Out of 12 Weeks
  • Table 29: Efficacy Responder Rates in Linzess' Two Placebo-Controlled IBS-C Trials: At Least Six Out of 12 Weeks
  • Table 30: Safety of Linzess - Most Frequently Reported Adverse Events
  • Table 31: Linzess SWOT Analysis, 2014
  • Table 32: Global IBS Sales Forecasts ($m) for Linzess, 2013-2023
  • Table 33: Product Profile - Lotronex
  • Table 34: Safety of Lotronex - Most Frequently Reported Adverse Events
  • Table 35: Lotronex SWOT Analysis, 2014
  • Table 36: Global IBS Sales Forecasts ($m) for Lotronex, 2013-2023
  • Table 37: Product Profile - Irribow
  • Table 38: Irribow SWOT Analysis, 2014
  • Table 39: Global IBS Sales Forecasts ($m) for Irribow, 2013-2023
  • Table 40: Use of Antidepressants in IBS, SWOT Analysis, 2014
  • Table 41: Global IBS Sales Forecasts ($m) for Antidepressants, 2013-2023
  • Table 42: Summary of Other Therapeutic Classes of Pharmacologics in IBS, 2014
  • Table 43: Unmet Needs and Opportunities in IBS
  • Table 44: Drugs in Late-Stage Clinical Development for IBS, 2014
  • Table 45: Product Profile - Eluxadoline
  • Table 46: Eluxadoline SWOT Analysis, 2014
  • Table 47: Global IBS Sales Forecasts ($m) for Eluxadoline, 2013-2023
  • Table 48: Product Profile - Ibodutant
  • Table 49: Ibodutant SWOT Analysis, 2014
  • Table 50: Global IBS Sales Forecasts ($m) for Ibodutant, 2013-2023
  • Table 51: Product Profile - Xifaxan
  • Table 52: Safety of Xifaxan - Most Frequently Reported Adverse Events
  • Table 53: Xifaxan SWOT Analysis, 2014
  • Table 54: Global IBS Sales Forecasts ($m) for Xifaxan, 2013-2023
  • Table 55: Product Profile - Plecanatide
  • Table 56: Plecanatide SWOT Analysis, 2014
  • Table 57: Global IBS Sales Forecasts ($m) for Plecanatide, 2013-2023
  • Table 58: Product Profile - Tenapanor
  • Table 59: Tenapanor SWOT Analysis, 2014
  • Table 60: Global IBS Sales Forecasts ($m) for Tenapanor, 2013-2023
  • Table 61: Drugs in Early-Stage Clinical Development for IBS, 2014
  • Table 62: Key Companies in the IBS Market in the 7MM, 2014
  • Table 63: Actavis' IBS Portfolio Assessment, 2014
  • Table 64: Astellas' IBS Portfolio Assessment, 2014
  • Table 65: Almirall's IBS Portfolio Assessment, 2014
  • Table 66: Ironwood's IBS Portfolio Assessment, 2014
  • Table 67: Takeda's IBS Portfolio Assessment, 2014
  • Table 68: Sucampo's IBS Portfolio Assessment, 2014
  • Table 69: Prometheus' IBS Portfolio Assessment, 2014
  • Table 70: Salix's IBS Portfolio Assessment, 2014
  • Table 71: Menarini's IBS Portfolio Assessment, 2014
  • Table 72: Synergy's IBS Portfolio Assessment, 2014
  • Table 73: AstraZeneca's IBS Portfolio Assessment, 2014
  • Table 74: Global Sales Forecasts ($m) for IBS, 2013-2023
  • Table 75: Global IBS Market - Drivers and Barriers, 2013-2023
  • Table 76: Sales Forecasts ($m) for IBS in the US, 2013-2023
  • Table 77: Key Events Impacting Sales for IBS in the US, 2013-2023
  • Table 78: IBS Market in the US - Drivers and Barriers, 2013-2023
  • Table 79: Sales Forecasts ($m) for IBS in France, 2013-2023
  • Table 80: Key Events Impacting Sales for IBS in France, 2013-2023
  • Table 81: IBS Market in France - Drivers and Barriers, 2013-2023
  • Table 82: Sales Forecasts ($m) for IBS in Germany, 2013-2023
  • Table 83: Key Events Impacting Sales for IBS in Germany, 2013-2023
  • Table 84: IBS Market in Germany - Drivers and Barriers, 2013-2023
  • Table 85: Sales Forecasts ($m) for IBS in Italy, 2013-2023
  • Table 86: Key Events Impacting Sales for IBS in Italy, 2013-2023
  • Table 87: IBS Market in Italy - Drivers and Barriers, 2013-2023
  • Table 88: Sales Forecasts ($m) for IBS in Spain, 2013-2023
  • Table 89: Key Events Impacting Sales for IBS in Spain, 2013-2023
  • Table 90: IBS Market in Spain - Drivers and Barriers, 2013-2023
  • Table 91: Sales Forecasts ($m) for IBS in the UK, 2013-2023
  • Table 92: Key Events Impacting Sales for IBS in the UK, 2013-2023
  • Table 93: IBS Market in the UK - Drivers and Barriers, 2013-2023
  • Table 94: Sales Forecasts ($m) for IBS in Japan, 2013-2023
  • Table 95: Key Events Impacting Sales for IBS in Japan, 2013-2023
  • Table 96: IBS Market in Japan - Drivers and Barriers, 2013-2023
  • Table 97: Key Launch Dates
  • Table 98: Key Patent Expiries
  • Table 99: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: 7MM, Total Prevalent Cases of IBS Ages ≥10 Years, Both Sexes, N, 2013-2023
  • Figure 2: 7MM, Age-Specific Total Prevalent Cases of IBS, Both Sexes, N, 2013
  • Figure 3: 7MM, Sex-Specific Total Prevalent Cases of IBS, Ages ≥10 Years, N, 2013
  • Figure 4: 7MM, Age-Standardized Total Prevalence of IBS (%), Ages ≥10 Years, by Sex, 2013
  • Figure 5: 7MM Total Prevalent Cases of IBS (%), by Clinical Subtype, Both Sexes, Ages ≥10 Years, 2013
  • Figure 6: Summary of Pharmacotherapies Used to Treat IBS
  • Figure 7: IBS Therapeutics - Clinical Trials by Therapy Type and Development Stage, October 2014
  • Figure 8: IBS - Phase IIb-III Pipeline, October 2014
  • Figure 9: Competitive Assessment of Late-Stage Pipeline Agents in IBS, 2013-2023
  • Figure 10: Clinical and Commercial Positioning of Eluxadoline
  • Figure 11: Clinical and Commercial Positioning of Ibodutant
  • Figure 12: Clinical and Commercial Positioning of Xifaxan
  • Figure 13: Clinical and Commercial Positioning of Plecanatide
  • Figure 14: Clinical and Commercial Positioning of Tenapanor
  • Figure 15: Company Portfolio Gap Analysis in IBS, 2013-2023
  • Figure 16: Actavis' SWOT Analysis in IBS, 2013-2023
  • Figure 17: Astellas' SWOT Analysis in IBS, 2013-2023
  • Figure 18: Almirall's SWOT Analysis in IBS, 2013-2023
  • Figure 19: Ironwood's SWOT Analysis in IBS, 2013-2023
  • Figure 20: Takeda's SWOT Analysis in IBS, 2013-2023
  • Figure 21: Sucampo's SWOT Analysis in IBS, 2013-2023
  • Figure 22: Prometheus' SWOT Analysis in IBS, 2013-2023
  • Figure 23: Salix's SWOT Analysis in IBS, 2013-2023
  • Figure 24: Menarini's SWOT Analysis in IBS, 2013-2023
  • Figure 25: Synergy's SWOT Analysis in IBS, 2013-2023
  • Figure 26: AstraZeneca's SWOT Analysis in IBS, 2013-2023
  • Figure 27: Global Sales for IBS by Region, 2013-2023
  • Figure 28: Sales for IBS in the US by Therapy Type, 2013-2023
  • Figure 29: Sales for IBS in France by Therapy Type, 2013-2023
  • Figure 30: Sales for IBS in Germany by Therapy Type, 2013-2023
  • Figure 31: Sales for IBS in Italy by Therapy Type, 2013-2023
  • Figure 32: Sales for IBS in Spain by Therapy Type, 2013-2023
  • Figure 33: Sales for IBS in the UK by Therapy Type, 2013-2023
  • Figure 34: Sales for IBS in Japan by Therapy Type, 2013-2023
Back to Top